Agilent Technologies Inc (NYSE:A) CEO Sells $1,909,212.50 in Stock

Agilent Technologies Inc (NYSE:A) CEO Michael R. Mcmullen sold 24,635 shares of Agilent Technologies stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $77.50, for a total transaction of $1,909,212.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of NYSE A traded down $0.75 during mid-day trading on Monday, reaching $77.15. 2,862,699 shares of the company’s stock traded hands, compared to its average volume of 2,348,355. Agilent Technologies Inc has a 1-year low of $61.01 and a 1-year high of $82.27. The stock has a market cap of $24.01 billion, a P/E ratio of 27.65, a PEG ratio of 2.14 and a beta of 1.40. The business has a 50-day simple moving average of $70.45 and a 200 day simple moving average of $73.97. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.13 and a quick ratio of 1.72.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 14th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. Agilent Technologies had a net margin of 21.06% and a return on equity of 20.00%. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities research analysts anticipate that Agilent Technologies Inc will post 3.08 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 price target for the company. in a research note on Monday, August 19th. Needham & Company LLC lifted their price objective on shares of Agilent Technologies to $92.00 and gave the company a “buy” rating in a report on Monday, August 19th. Barclays cut shares of Agilent Technologies from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $86.00 to $78.00 in a report on Monday, July 15th. ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, July 12th. Finally, Bank of America cut shares of Agilent Technologies from a “buy” rating to a “neutral” rating and set a $76.00 price objective for the company. in a report on Tuesday, July 16th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.77.

Institutional investors have recently added to or reduced their stakes in the stock. Edgestream Partners L.P. purchased a new position in Agilent Technologies during the second quarter worth about $2,616,000. Skandinaviska Enskilda Banken AB publ raised its position in Agilent Technologies by 2.6% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 66,135 shares of the medical research company’s stock worth $4,938,000 after acquiring an additional 1,654 shares during the period. HighTower Advisors LLC raised its position in Agilent Technologies by 1,183.0% in the second quarter. HighTower Advisors LLC now owns 122,800 shares of the medical research company’s stock worth $9,132,000 after acquiring an additional 113,229 shares during the period. Prentiss Smith & Co. Inc. raised its position in Agilent Technologies by 484.9% in the second quarter. Prentiss Smith & Co. Inc. now owns 58,428 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 48,438 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in Agilent Technologies by 0.7% in the first quarter. TimesSquare Capital Management LLC now owns 1,007,700 shares of the medical research company’s stock worth $80,999,000 after acquiring an additional 7,200 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: What member countries make up the G-20?

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.